Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.Translational cancer research · 2020
   Review
2. Traditional Classification and Novel Subtyping Systems for Bladder Cancer.Frontiers in oncology · 2020
   Review

Corrections and comments

• Comment on
  Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.2019

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as